Suppliers and packagers for JENCYCLA

JENCYCLA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lupin Ltd	JENCYCLA	norethindrone	TABLET;ORAL-28	091323	ANDA	Lupin Pharmaceuticals, Inc.	68180-877-73	1 BLISTER PACK in 1 CARTON (68180-877-73) / 28 TABLET in 1 BLISTER PACK	2020-07-07

Last updated: August 18, 2025

ppliers for the Pharmaceutical Drug: Jencycla

Introduction

Jencycla, known generically as an oral contraceptive, is a combination medication primarily used for pregnancy prevention. It combines ethinyl estradiol and desogestrel, components found in various contraceptive formulations. As a specialized pharmaceutical product, sourcing reliable suppliers is critical for manufacturers, distributors, and healthcare providers to ensure quality, compliance, and consistent supply. This report explores the landscape of Jencycla suppliers, focusing on authorized distributors, manufacturing sources, and the global distribution infrastructure.

Overview of Jencycla

Jencycla is classified as a combined oral contraceptive (COC). Its active pharmaceutical ingredients (APIs)—ethinyl estradiol and desogestrel—are well-established, with extensive manufacturing and supply networks. The drug is marketed under various brand names and generic equivalents worldwide. Its key sources often overlap with those supplying the APIs and finished formulations for contraceptive products.

Manufacturers and Brand Owners

Jencycla is produced by pharmaceutical companies operating under strict regulatory compliance, often approved by agencies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency). Production entails sourcing high-quality APIs, pre-formulation processes, and final formulation and packaging.

While specific proprietary information about Jencycla's production site details remains proprietary, the key manufacturers involved in similar combined contraceptive formulations include:

• Janssen Pharmaceuticals: A major producer of oral contraceptive formulations, including products with desogestrel and ethinyl estradiol. Janssen’s robust manufacturing facilities often serve as a source for licensed contraceptives.
• Gedeon Richter: A European pharmaceutical company with extensive contraceptive product lines, including combination pills.
• Sandoz (Novartis): Known for producing generic hormones used in contraceptive formulations.
• Mithra Pharmaceuticals: Specializes in hormonal contraceptives with a focus on innovative delivery systems.

Note: The specific supplier for Jencycla formulation may vary depending on the regional distributor and licensing agreements.

API Suppliers for Ethinyl Estradiol and Desogestrel

The core APIs in Jencycla are sourced globally. These suppliers predominantly supply APIs to pharmaceutical companies for formulation production. The following are leading API suppliers:

• Suzhou Beta Pharmaceutical Co., Ltd. (China): A significant supplier of ethinyl estradiol, with GMP certification.
• Hubei Yiming Pharmaceutical Co., Ltd. (China): Produces bulk APIs including desogestrel.
• LGM Pharma: A global distributor providing APIs like ethinyl estradiol, with verified quality standards.
• Daiichi Sankyo (Japan): A historical supplier of high-quality hormonal APIs, including ethinyl estradiol.
• Shanghai Sine Pharmaceutical Chemical Co., Ltd.: Another Chinese API manufacturer with GMP-certified production lines.

Many multinational pharmaceutical companies source APIs from these suppliers, integrating them into finished formulations or licensing production to regional manufacturers.

Authorized Distributors and Supply Chain Actors

In the context of Jencycla, authorized distributors typically operate under licensing agreements with the regional marketing authorization holder (MAH). Their role involves ensuring product integrity, regulatory compliance, and supply chain security.

Key regional players include:

• Pfizer: As a licensed distributor or market holder for various contraceptive products in North America.
• Mundipharma: In Europe, often involved in distributing contraceptive medicines.
• Local Generic Manufacturers and Importers: In emerging markets, local companies often import finished formulations from licensed foreign manufacturers or API APIs for local compounding.

Regulatory and Supply Chain Considerations

Given the sensitive nature of hormonal contraceptives, regulatory compliance with Good Manufacturing Practices (GMP) and traceability is paramount. The supply chain involves multiple stakeholders:

• API Manufacturers: Responsible for producing high-quality, GMP-compliant APIs.
• Formulation Manufacturers: Combine APIs into finished products under strict quality control.
• Wholesalers & Distributors: Handle logistics, warehousing, and legal documentation.
• Healthcare Providers & Pharmacies: End-point suppliers who dispense Jencycla.

Due to regional regulatory variations, some manufacturers source APIs from different suppliers, leading to variability in supply options for the same formulation.

Emerging Trends and Future Outlook

The pharmaceutical supply landscape for contraceptives like Jencycla is evolving with increased emphasis on:

• Global Supply Chain Diversification: To mitigate risks associated with reliance on a limited number of API sources.
• Generic Competition: Expanding access through licensed generics, requiring robust supply channels.
• Quality Assurance Initiatives: Ensuring API and finished product authenticity amidst increasing counterfeiting threats.

Manufacturers are increasingly seeking partnerships with API suppliers who demonstrate compliance with international standards like GMP, GDP (Good Distribution Practice), and ISO certifications.

Conclusion

Suppliers of Jencycla encompass a broad network, including global API manufacturers, formulation producers, and regional distributors, all operating within a regulated environment. Ensuring a reliable supply chain relies heavily on partnerships with GMP-certified API providers, licensing agreements with reputable formulation manufacturers, and compliant distribution channels.

---

Key Takeaways

• Diverse API Sources: Major API suppliers for ethinyl estradiol and desogestrel are primarily based in China and Japan, with global distributors facilitating access.
• Manufacturing Partnerships: Leading pharmaceutical companies like Janssen and Gedeon Richter are key formulators of Jencycla or similar contraceptives.
• Regulatory Vigilance: Regulatory compliance and quality assurance are vital in maintaining supply integrity.
• Supply Chain Reliability: Regional distributors and authorized importers serve as linchpins in getting Jencycla to market, especially in emerging markets.
• Future Trends: Emphasizing diversification of API sources and strengthened QA processes to combat counterfeiting and supply disruptions.

---

FAQs

1. Who are the primary API suppliers for Jencycla?
Major API suppliers for ethinyl estradiol and desogestrel include Chinese GMP-certified manufacturers such as Suzhou Beta Pharmaceutical Co., Ltd. and Hubei Yiming Pharmaceutical Co., Ltd., as well as Japanese and European producers like Daiichi Sankyo.

2. Can generic versions of Jencycla be sourced internationally?
Yes, various generic contraceptive formulations with similar active ingredients are available globally through licensed manufacturers and authorized distributors, often with identical APIs.

3. What quality standards do suppliers of Jencycla adhere to?
Suppliers typically comply with international standards like GMP, ISO, and GDP, ensuring API quality, manufacturing integrity, and supply chain security.

4. How has the supply chain for contraceptives like Jencycla evolved recently?
The supply chain has shifted toward increased diversification of API sources, digital tracking, and stricter regulatory oversight to enhance security, quality, and supply resilience.

5. Are there regional differences in Jencycla supply sources?
Yes. Developed markets generally source from established multinational API suppliers and formulation firms, while emerging markets may rely more on regional generic manufacturers and import mechanisms.

---

References

1. [1] European Medicines Agency. (2022). Contraceptive drugs overview.
2. [2] U.S. FDA. (2021). Approved drug products with therapeutic equivalence evaluations.
3. [3] LGM Pharma. (2022). Hormone APIs and sources.
4. [4] Gedeon Richter. (2022). Product portfolio and manufacturing standards.
5. [5] Sourcing Industry Practice. (2023). Global pharmaceutical API markets.